cancernetwork.com
Jan 18, 2025, 21:04
Ponsegromab reduces symptoms linked to cancer cachexia, elevated GDF-15
Amy C. Moore, Vice President of Global Engagement and Patient Partnerships at LUNGevity Foundation, shared a post on LinkedIn:
“This study is an important advance forward for patients impacted by cancer cachexia, which is characterized by extreme weight loss without trying.
The drug improved weight gain, activity levels and other indicators.”
Dr. Amy C. Moore is the Vice President of Global Engagement and Patient Partnerships at LUNGevity Foundation. She previously served as the Director of Science and Research at the Addario Lung Cancer Medical Institute (ALCMI). She has published peer-reviewed papers on virology, cancer, and biomarker testing in NSCLC. Dr. Moore is also an
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 1, 2025, 19:24
Aug 1, 2025, 19:14
Aug 1, 2025, 18:32